Cargando…
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review hig...
Autores principales: | O'Connor, J P B, Jackson, A, Parker, G J M, Jayson, G C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359994/ https://www.ncbi.nlm.nih.gov/pubmed/17211479 http://dx.doi.org/10.1038/sj.bjc.6603515 |
Ejemplares similares
-
Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009) -
The clinical potential of antiangiogenic fragments of extracellular matrix proteins
por: Clamp, A R, et al.
Publicado: (2005) -
Vascular disrupting agents in clinical development
por: Hinnen, P, et al.
Publicado: (2007) -
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011) -
Heterogeneity of Tumor Vasculature and Antiangiogenic Intervention: Insights from MR Angiography and DCE-MRI
por: Zhu, Wenlian, et al.
Publicado: (2014)